Orchid Pharma - Enmetazobactam, First Indian NCE Gets U.S. FDA Nod: Systematix

We revise our target price on Orchid pharma at Rs. 1,057 as we raise our target price-to-earnings multiple from 30 times to 33 times.

<div class="paragraphs"><p>(Source: Louis Reed on Unsplash)</p></div>
(Source: Louis Reed on Unsplash)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More